Welcome!

News Feed Item

The 15th Annual BioEquity Europe Conference Features More Than 100 Innovator Companies With Differentiated Products, Upcoming Milestones and Partner-Ready Assets

Two Days of Plenary Sessions Examine How European Companies Are Stepping Up to Play in Biotech's Premier League

REDWOOD CITY, CA -- (Marketwired) -- 05/20/14 -- BioCentury, EBD Group and the Biotechnology Industry Organization (BIO) will convene the 15th Annual BioEquity Europe conference in Amsterdam on Wednesday, May 21, and Thursday, May 22, at the Hilton Amsterdam Hotel. More than 500 life science investment professionals and pharmaceutical business development and licensing executives have registered. Walk-up registration is available at the Hilton Amsterdam Hotel starting at 7:45 a.m. on May 21.

BioEquity Europe is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects.

In 2014, the conference will showcase presentations by 68 mature and 42 newly formed innovator biopharma companies. The Presenting Companies have been hand-picked by BioCentury on the basis of investor validation, upcoming milestones and unpartnered assets. The slate of Next Wave Companies features fresh opportunities for venture capital investment and early stage partnering opportunities in the biotech space.

More than half a dozen plenaries and Q&A sessions over the two days will feature 45 key opinion leaders. These sessions will be highlighted by a fireside chat with Dr. Jordi Llinares-Garcia -- EMA's Head of Product Development Scientific Support Department and former Head of Orphan Drugs. During this session, BioCentury's Chairman & Editor-in-Chief Dr. Karen Bernstein will interview Dr. Llinares-Garcia about how the agency acts as an "enabler" for smaller players, including academia, in the pharmaceutical innovation ecosystem.

Back by popular demand is the BioCentury/Ernst & Young Face-Off. At the Face-Off, BioCentury will unveil its 12th annual "European Iceberg" report, which projects funding demands by Europe's clinical stage biotechnology companies, and Ernst & Young will provide analysis from its 28th annual "Beyond Borders Global Biotechnology Report." The Face-Off will be chaired by Susan Schaeffer, Editor of BioCentury, and Jürg Zürcher, Partner, EMEIA Biotechnology Leader, Ernst & Young.

Other plenaries will focus on how European biotechs can better compete with U.S. companies for capital, and how European science stands up against a global playing field.

"The full slate of presenting companies, distinguished faculty and strong pre-registration numbers indicate a renewed interest in European biotechs by the investment and licensing communities," said BioCentury Publisher Eric Pierce. "The compelling stories from the Class of 2014, coupled with high-impact discussions with our international faculty, make BioEquity Europe a must-attend event for investors and business development and licensing professionals."

See the complete program, including presenting companies, plenary schedules and a list of the 2014 faculty at http://www.biocentury.com/conferences/bioequityeurope/dates/schedule.

The 2014 BioEquity Europe Presenting Companies
Presenting companies were screened using BioCentury's industry analysis and proprietary databases, including BioCentury's BCIQ online business intelligence platform. The result is an independently selected mix of companies with proven fundraising ability, prospects for key partnerships and proximity to potentially transformational milestones.

View the complete list of presenting companies and Next Wave Presenting Companies at http://www.biocentury.com/conferences/bioequityeurope/companies/presentingcompanies.

The BioEquity Europe Sponsors & Regional Host Committee
This unique turf-neutral setting is made possible by the support of the region's life science organizations and BioEquity Europe's Sponsors. The Regional Host Committee is comprised of Amsterdam BioMed Cluster/Amsterdam Economic Board, Axon, Deloitte and Van Campen Liem.

The prestigious group of 2014 sponsors is anchored by Gold Sponsors Ernst & Young, MS Ventures and Sofinnova Partners and Silver Sponsors Abingworth, AstraZeneca, Boehringer Ingelheim Venture Fund, Edwards Wildman, Geller Biopharm, Gilde Healthcare, Index Ventures, Inserm Transfert Initiative, Johnson & Johnson Innovation, LSP-Life Sciences Partners, Oxford Finance, Piper Jaffray and Roche Venture Fund.

About BioCentury
Since 1993, BioCentury Publications, Inc. has provided essential biopharma industry intelligence to a global audience of biotech and pharmaceutical executives, investors, regulators and public policy makers, and the scientific community. This audience has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, television, data products and collaborative industry conferences in the U.S., Europe and Asia.

BioEquity Europe is one of three annual investor conferences organized by BioCentury. The next conference, NewsMakers in the Biotech Industry, will take place on Sept. 26, 2014, followed by Future Leaders in the Biotech Industry, on March 20, 2015. Both events will take place at the Millennium Broadway Hotel & Conference Center in New York City.

For more information, visit www.biocentury.com and www.biocenturytv.com.

About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group's conferences are run with the support of leading corporations and international trade associations and include:

  • BIO-Europe® and BIO-Europe Spring®, supported by the Biotechnology Industry Organization (BIO)
  • BioPharm America™
  • Biotech Showcase™, co-produced with Demy-Colton Life Science Advisors
  • BioEquity Europe, co-organized with BioCentury Publications and BIO
  • ChinaBio® Partnering Forum, co-produced with ChinaBio® LLC
  • EuroMedtech™
  • Partnering for Global Impact®

EBD Group's sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.

EBD Group is an Informa company. Informa is the largest publicly owned organizer of exhibitions, conferences and training in the world.

EBD Group has offices in the USA and Europe.

About the Biotechnology Industry Organization
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the U.S. and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
"Storpool does only block-level storage so we do one thing extremely well. The growth in data is what drives the move to software-defined technologies in general and software-defined storage," explained Boyan Ivanov, CEO and co-founder at StorPool, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Sometimes I write a blog just to formulate and organize a point of view, and I think it’s time that I pull together the bounty of excellent information about Machine Learning. This is a topic with which business leaders must become comfortable, especially tomorrow’s business leaders (tip for my next semester University of San Francisco business students!). Machine learning is a key capability that will help organizations drive optimization and monetization opportunities, and there have been some...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, provided a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to oper...
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Is advanced scheduling in Kubernetes achievable?Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, answered these questions and demonstrated techniques for implementing advanced scheduling. For example, using spot instances and co...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.